1fak › Citations

Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.

Zhang E, St Charles R, Tulinsky A
J Mol Biol 285 2089-104 (1999)
Cited: 69 times
EuropePMC logo PMID: 9925787

Abstract

The event that initiates the extrinsic pathway of blood coagulation is the association of coagulation factor VIIa (VIIa) with its cell-bound receptor, tissue factor (TF), exposed to blood circulation following tissue injury and/or vascular damage. The natural inhibitor of the TF.VIIa complex is the first Kunitz domain of tissue factor pathway inhibitor (TFPI-K1). The structure of TF. VIIa reversibly inhibited with a potent (Ki=0.4 nM) bovine pancreatic trypsin inhibitor (BPTI) mutant (5L15), a homolog of TFPI-K1, has been determined at 2.1 A resolution. When bound to TF, the four domain VIIa molecule assumes an extended conformation with its light chain wrapping around the framework of the two domain TF cofactor. The 5L15 inhibitor associates with the active site of VIIa similar to trypsin-bound BPTI, but makes several unique interactions near the perimeter of the site that are not observed in the latter. Most of the interactions are polar and involve mutated positions of 5L15. Of the eight rationally engineered mutations distinguishing 5L15 from BPTI, seven are involved in productive interactions stabilizing the enzyme-inhibitor association with four contributing contacts unique to the VIIa.5L15 complex. Two additional unique interactions are due to distinguishing residues in the VIIa sequence: a salt bridge between Arg20 of 5L15 and Asp60 of an insertion loop of VIIa, and a hydrogen bond between Tyr34O of the inhibitor and Lys192NZ of the enzyme. These interactions were used further to model binding of TFPI-K1 to VIIa and TFPI-K2 to factor Xa, the principal activation product of TF.VIIa. The structure of the ternary protein complex identifies the determinants important for binding within and near the active site of VIIa, and provides cogent information for addressing the manner in which substrates of VIIa are bound and hydrolyzed in blood coagulation. It should also provide guidance in structure-aided drug design for the discovery of potent and selective small molecule VIIa inhibitors.

Reviews - 1fak mentioned but not cited (1)

  1. Machine Learning Approaches for Protein⁻Protein Interaction Hot Spot Prediction: Progress and Comparative Assessment. Liu S, Liu C, Deng L. Molecules 23 E2535 (2018)

Articles - 1fak mentioned but not cited (20)

  1. Anchor residues in protein-protein interactions. Rajamani D, Thiel S, Vajda S, Camacho CJ. Proc Natl Acad Sci U S A 101 11287-11292 (2004)
  2. Benchmarking and analysis of protein docking performance in Rosetta v3.2. Chaudhury S, Berrondo M, Weitzner BD, Muthu P, Bergman H, Gray JJ. PLoS One 6 e22477 (2011)
  3. Protein-protein docking benchmark version 3.0. Hwang H, Pierce B, Mintseris J, Janin J, Weng Z. Proteins 73 705-709 (2008)
  4. SwarmDock and the use of normal modes in protein-protein docking. Moal IH, Bates PA. Int J Mol Sci 11 3623-3648 (2010)
  5. PPCheck: A Webserver for the Quantitative Analysis of Protein-Protein Interfaces and Prediction of Residue Hotspots. Sukhwal A, Sowdhamini R. Bioinform Biol Insights 9 141-151 (2015)
  6. Protein-protein binding site identification by enumerating the configurations. Guo F, Li SC, Wang L, Zhu D. BMC Bioinformatics 13 158 (2012)
  7. Identification of hot regions in protein-protein interactions by sequential pattern mining. Hsu CM, Chen CY, Liu BJ, Huang CC, Laio MH, Lin CC, Wu TL. BMC Bioinformatics 8 Suppl 5 S8 (2007)
  8. Pre- and post-docking sampling of conformational changes using ClustENM and HADDOCK for protein-protein and protein-DNA systems. Kurkcuoglu Z, Bonvin AMJJ. Proteins 88 292-306 (2020)
  9. Beauty is in the eye of the beholder: proteins can recognize binding sites of homologous proteins in more than one way. Martin J. PLoS Comput Biol 6 e1000821 (2010)
  10. Heparin modulates the 99-loop of factor IXa: effects on reactivity with isolated Kunitz-type inhibitor domains. Neuenschwander PF, Williamson SR, Nalian A, Baker-Deadmond KJ. J Biol Chem 281 23066-23074 (2006)
  11. How to use not-always-reliable binding site information in protein-protein docking prediction. Li L, Huang Y, Xiao Y. PLoS One 8 e75936 (2013)
  12. Predicting where small molecules bind at protein-protein interfaces. Walter P, Metzger J, Thiel C, Helms V. PLoS One 8 e58583 (2013)
  13. Computational alanine scanning with linear scaling semiempirical quantum mechanical methods. Diller DJ, Humblet C, Zhang X, Westerhoff LM. Proteins 78 2329-2337 (2010)
  14. Deciphering the shape and deformation of secondary structures through local conformation analysis. Baussand J, Camproux AC. BMC Struct Biol 11 9 (2011)
  15. Analysis of binding properties and specificity through identification of the interface forming residues (IFR) for serine proteases in silico docked to different inhibitors. Ribeiro C, Togawa RC, Neshich IA, Mazoni I, Mancini AL, Minardi RC, da Silveira CH, Jardine JG, Santoro MM, Neshich G. BMC Struct Biol 10 36 (2010)
  16. Prediction of hot spots in protein interfaces using extreme learning machines with the information of spatial neighbour residues. Wang L, Zhang W, Gao Q, Xiong C. IET Syst Biol 8 184-190 (2014)
  17. Applying Side-chain Flexibility in Motifs for Protein Docking. Liu H, Lin F, Yang JL, Wang HR, Liu XL. Genomics Insights 8 1-10 (2015)
  18. Predicting Protein Functional Motions: an Old Recipe with a New Twist. Grudinin S, Laine E, Hoffmann A. Biophys J 118 2513-2525 (2020)
  19. Protein docking with predicted constraints. Krippahl L, Barahona P. Algorithms Mol Biol 10 9 (2015)
  20. Mutations of TFPI-binding exosites on factor VII cause bleeding phenotypes in factor VII deficiency. Seanoon K, Payongsri P, Vivithanaporn P, Sirachainan N, Chuansumrit A, Hongeng S, Tanratana P. Blood Adv 6 5887-5897 (2022)


Reviews citing this publication (7)

  1. Interleukin-10 and related cytokines and receptors. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Annu Rev Immunol 22 929-979 (2004)
  2. The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. Monroe DM, Key NS. J Thromb Haemost 5 1097-1105 (2007)
  3. Tissue factor: (patho)physiology and cellular biology. Eilertsen KE, Østerud B. Blood Coagul Fibrinolysis 15 521-538 (2004)
  4. Quantitative account of the enhanced affinity of two linked scFvs specific for different epitopes on the same antigen. Zhou HX. J Mol Biol 329 1-8 (2003)
  5. Structural biology of factor VIIa/tissue factor initiated coagulation. Vadivel K, Bajaj SP. Front Biosci (Landmark Ed) 17 2476-2494 (2012)
  6. Recent estimates of the structure of the factor VIIa (FVIIa)/tissue factor (TF) and factor Xa (FXa) ternary complex. Lee CJ, Chandrasekaran V, Wu S, Duke RE, Pedersen LG. Thromb Res 125 Suppl 1 S7-S10 (2010)
  7. Protein anticoagulants targeting factor VIIa-tissue factor complex: a comprehensive review. Shah K, Bayoumi R, Banerjee Y. Hematology 18 1-7 (2013)

Articles citing this publication (41)

  1. Peptide exosite inhibitors of factor VIIa as anticoagulants. Dennis MS, Eigenbrot C, Skelton NJ, Ultsch MH, Santell L, Dwyer MA, O'Connell MP, Lazarus RA. Nature 404 465-470 (2000)
  2. Protein-protein interactions: hot spots and structurally conserved residues often locate in complemented pockets that pre-organized in the unbound states: implications for docking. Li X, Keskin O, Ma B, Nussinov R, Liang J. J Mol Biol 344 781-795 (2004)
  3. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Persson E, Kjalke M, Olsen OH. Proc Natl Acad Sci U S A 98 13583-13588 (2001)
  4. Structure of human factor VIIa and its implications for the triggering of blood coagulation. Pike AC, Brzozowski AM, Roberts SM, Olsen OH, Persson E. Proc Natl Acad Sci U S A 96 8925-8930 (1999)
  5. Isolation, cloning and structural characterisation of boophilin, a multifunctional Kunitz-type proteinase inhibitor from the cattle tick. Macedo-Ribeiro S, Almeida C, Calisto BM, Friedrich T, Mentele R, Stürzebecher J, Fuentes-Prior P, Pereira PJ. PLoS One 3 e1624 (2008)
  6. Thrombosis in inherited factor VII deficiency. Mariani G, Herrmann FH, Schulman S, Batorova A, Wulff K, Etro D, Dolce A, Auerswald G, Astermark J, Schved JF, Ingerslev J, Bernardi F, International Factor VII Deficiency Study Group. J Thromb Haemost 1 2153-2158 (2003)
  7. The factor VII zymogen structure reveals reregistration of beta strands during activation. Eigenbrot C, Kirchhofer D, Dennis MS, Santell L, Lazarus RA, Stamos J, Ultsch MH. Structure 9 627-636 (2001)
  8. Crystal structures of uninhibited factor VIIa link its cofactor and substrate-assisted activation to specific interactions. Sichler K, Banner DW, D'Arcy A, Hopfner KP, Huber R, Bode W, Kresse GB, Kopetzki E, Brandstetter H. J Mol Biol 322 591-603 (2002)
  9. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. Shia S, Stamos J, Kirchhofer D, Fan B, Wu J, Corpuz RT, Santell L, Lazarus RA, Eigenbrot C. J Mol Biol 346 1335-1349 (2005)
  10. Substitutions at the P(1) position in BPTI strongly affect the association energy with serine proteinases. Grzesiak A, Helland R, Smalås AO, Krowarsch D, Dadlez M, Otlewski J. J Mol Biol 301 205-217 (2000)
  11. The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis. Norledge BV, Petrovan RJ, Ruf W, Olson AJ. Proteins 53 640-648 (2003)
  12. Structure-function analysis of the reactive site in the first Kunitz-type domain of human tissue factor pathway inhibitor-2. Chand HS, Schmidt AE, Bajaj SP, Kisiel W. J Biol Chem 279 17500-17507 (2004)
  13. Properties of spin and fluorescent labels at a receptor-ligand interface. Owenius R, Osterlund M, Lindgren M, Svensson M, Olsen OH, Persson E, Freskgård PO, Carlsson U. Biophys J 77 2237-2250 (1999)
  14. Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement. Persson E, Bak H, Østergaard A, Olsen OH. Biochem J 379 497-503 (2004)
  15. Characterization of mutations causing factor VII deficiency in 61 unrelated Israeli patients. Fromovich-Amit Y, Zivelin A, Rosenberg N, Tamary H, Landau M, Seligsohn U. J Thromb Haemost 2 1774-1781 (2004)
  16. Engineering of substrate selectivity for tissue factor.factor VIIa complex signaling through protease-activated receptor 2. Larsen KS, Ostergaard H, Olsen OH, Bjelke JR, Ruf W, Petersen LC. J Biol Chem 285 19959-19966 (2010)
  17. Crystal structure of Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in complex with trypsin. Implications for KD1 specificity of inhibition. Schmidt AE, Chand HS, Cascio D, Kisiel W, Bajaj SP. J Biol Chem 280 27832-27838 (2005)
  18. High-resolution structure of bovine pancreatic trypsin inhibitor with altered binding loop sequence. Czapinska H, Otlewski J, Krzywda S, Sheldrick GM, Jaskólski M. J Mol Biol 295 1237-1249 (2000)
  19. Engineering kunitz domain 1 (KD1) of human tissue factor pathway inhibitor-2 to selectively inhibit fibrinolysis: properties of KD1-L17R variant. Bajaj MS, Ogueli GI, Kumar Y, Vadivel K, Lawson G, Shanker S, Schmidt AE, Bajaj SP. J Biol Chem 286 4329-4340 (2011)
  20. A combined structural dynamics approach identifies a putative switch in factor VIIa employed by tissue factor to initiate blood coagulation. Olsen OH, Rand KD, Østergaard H, Persson E. Protein Sci 16 671-682 (2007)
  21. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA). Katz BA, Luong C, Ho JD, Somoza JR, Gjerstad E, Tang J, Williams SR, Verner E, Mackman RL, Young WB, Sprengeler PA, Chan H, Mortara K, Janc JW, McGrath ME. J Mol Biol 344 527-547 (2004)
  22. Binding of Zn2+ to a Ca2+ loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor. Petersen LC, Olsen OH, Nielsen LS, Freskgård PO, Persson E. Protein Sci 9 859-866 (2000)
  23. NMR structure and backbone dynamics of a concatemer of epidermal growth factor homology modules of the human low-density lipoprotein receptor. Kurniawan ND, Aliabadizadeh K, Brereton IM, Kroon PA, Smith R. J Mol Biol 311 341-356 (2001)
  24. A Machine Learning Approach for Hot-Spot Detection at Protein-Protein Interfaces. Melo R, Fieldhouse R, Melo A, Correia JD, Cordeiro MN, Gümüş ZH, Costa J, Bonvin AM, Moreira IS. Int J Mol Sci 17 E1215 (2016)
  25. Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activation. Zivelin A, Ogawa T, Bulvik S, Landau M, Toomey JR, Lane J, Seligsohn U, Gailani D. J Thromb Haemost 2 1782-1789 (2004)
  26. Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changes. Persson E, Olsen OH. Eur J Biochem 269 5950-5955 (2002)
  27. Mechanism of the Ca2+-induced enhancement of the intrinsic factor VIIa activity. Bjelke JR, Olsen OH, Fodje M, Svensson LA, Bang S, Bolt G, Kragelund BB, Persson E. J Biol Chem 283 25863-25870 (2008)
  28. Predicted solution structure of zymogen human coagulation FVII. Perera L, Darden TA, Pedersen LG. J Comput Chem 23 35-47 (2002)
  29. Active and exo-site inhibition of human factor Xa: structure of des-Gla factor Xa inhibited by NAP5, a potent nematode anticoagulant protein from Ancylostoma caninum. Rios-Steiner JL, Murakami MT, Tulinsky A, Arni RK. J Mol Biol 371 774-786 (2007)
  30. Activation loop 3 and the 170 loop interact in the active conformation of coagulation factor VIIa. Persson E, Olsen OH. FEBS J 276 3099-3109 (2009)
  31. Crystal structure of tissue factor in complex with antibody 10H10 reveals the signaling epitope. Teplyakov A, Obmolova G, Malia TJ, Wu B, Zhao Y, Taudte S, Anderson GM, Gilliland GL. Cell Signal 36 139-144 (2017)
  32. Disulfide locked variants of factor VIIa with a restricted beta-strand conformation have enhanced enzymatic activity. Maun HR, Eigenbrot C, Raab H, Arnott D, Phu L, Bullens S, Lazarus RA. Protein Sci 14 1171-1180 (2005)
  33. Of four mutations in the factor VII gene in Tunisian patients, one novel mutation (Ser339Phe) in three unrelated families abrogates factor X activation. Fromovich-Amit Y, Zivelin A, Rosenberg N, Landau M, Rosa JP, Seligsohn U. Blood Coagul Fibrinolysis 16 369-374 (2005)
  34. Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold. Bolton SA, Sutton JC, Anumula R, Bisacchi GS, Jacobson B, Slusarchyk WA, Treuner UD, Wu SC, Zhao G, Pi Z, Sheriff S, Smirk RA, Bisaha S, Cheney DL, Wei A, Schumacher WA, Hartl KS, Liu E, Zahler R, Seiler SM. Bioorg Med Chem Lett 23 5239-5243 (2013)
  35. Macromolecular substrate affinity for free factor VIIa is independent of a buried protease domain N-terminus. Persson E. Biochem Biophys Res Commun 341 28-32 (2006)
  36. Design, parallel synthesis, and crystal structures of biphenyl antithrombotics as selective inhibitors of tissue factor FVIIa complex. Part 1: Exploration of S2 pocket pharmacophores. Kotian PL, Krishnan R, Rowland S, El-Kattan Y, Saini SK, Upshaw R, Bantia S, Arnold S, Babu YS, Chand P. Bioorg Med Chem 17 3934-3958 (2009)
  37. Expression and characterization of Kunitz domain 3 and C-terminal of human tissue factor pathway inhibitor-2. Zhu L, Wang J, Mu J, Wang H, Zhang C, Wang J, Liu X, Yan X, Dai L, Ma D. Acta Biochim Biophys Sin (Shanghai) 41 948-954 (2009)
  38. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain. Augustsson C, Svensson A, Kjaer B, Chao TY, Wenjuan X, Krogh BO, Breinholt J, Clausen JT, Hilden I, Petersen HH, Petersen LC. J Thromb Haemost 16 893-904 (2018)
  39. Homology modeling and structural validation of tissue factor pathway inhibitor. Agrawal P, Thakur Z, Kulharia M. Bioinformation 9 808-812 (2013)
  40. Inhibitors of factor VIIa affect the interface between the protease domain and tissue factor. Carlsson K, Persson E, Carlsson U, Svensson M. Biochem Biophys Res Commun 349 1111-1116 (2006)
  41. How the tissue factor-VIIa complex keeps two substrates in the loop. Schulman S. J Thromb Haemost 19 52-54 (2021)


Quick links